The Leukemia and Lymphoma Society of Canada Revenue and Competitors
Estimated Revenue & Valuation
- The Leukemia and Lymphoma Society of Canada's estimated annual revenue is currently $12M per year.
- The Leukemia and Lymphoma Society of Canada's estimated revenue per employee is $140,000
Employee Data
- The Leukemia and Lymphoma Society of Canada has 86 Employees.
- The Leukemia and Lymphoma Society of Canada grew their employee count by -1% last year.
The Leukemia and Lymphoma Society of Canada's People
Name | Title | Email/Phone |
---|---|---|
1 | Business Unit Director | Reveal Email/Phone |
2 | Fund Development Director, Ontario | Reveal Email/Phone |
3 | Accountant | Reveal Email/Phone |
4 | Community Program Coordinator | Reveal Email/Phone |
5 | Business Development Lead | Reveal Email/Phone |
The Leukemia and Lymphoma Society of Canada Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4048.4M | 15728 | 6% | $24.6M | N/A |
What Is The Leukemia and Lymphoma Society of Canada?
The Leukemia & Lymphoma Society of Canada (LLSC) is a voluntary health agency dedicated to blood cancer. LLSC funds lifesaving blood cancer research across Canada and worldwide, and provides free information and support services. \n\nThe LLSC's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.\n\nOur strategy to achieve the mission is based on three areas of focus: research, patient support and advocacy. In 2017, we invested almost $7.4 million in the creation of programs and delivery of services to improve the lives of Canadians affected by blood cancers from coast to coast. This investment included a commitment of over $4.1 million in innovative, life-changing research to accelerate new cancer treatments, therapies, and cures; and $3.3 million towards funding patient services, programs and education across Canada.\n\nWe do not charge patients, caregivers or healthcare professionals anything for any of the programs or materials we provide to them, but everything we do has costs associated with it. We do our best to minimize costs, while still ensuring the quality of the program or resource.
keywords:N/AN/A
Total Funding
86
Number of Employees
$12M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
The Leukemia and Lymphoma Society of Canada News
Candidates raise money in honor of a young, local patient hero who is battling or in remission from a blood cancer. The candidate or team...
Since its founding, LLS has helped expand what's possible for blood cancer patients, investing more than $1.5 billion in blood cancer research...
Leukemia is a cancer of the blood cells. There are several broad categories of blood cells, including red blood cells (RBCs), white blood cells...
pERC recommends reimbursement of VENCLEXTA® (venetoclax) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy. The VIALE-A trial demonstrated a statistically significant increase in overall survi ...
TORONTO, July 26, 2021 (GLOBE NEWSWIRE) -- Despite an extraordinarily challenging year, UFCW Canada members and Local Unions were undeterred in their extraordinary ongoing fundraising efforts, raising more than $2.1 million dollars in their latest annual campaign to support the lifesaving and li ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $12.5M | 86 | -7% | N/A |
#2 | $12.5M | 86 | 5% | $3M |
#3 | $28M | 86 | -7% | N/A |
#4 | $21.5M | 86 | 1% | N/A |
#5 | $12.9M | 86 | 6% | N/A |